Valid for Submission
C76.8 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of other specified ill-defined sites. The code C76.8 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.
The ICD-10-CM code C76.8 might also be used to specify conditions or terms like abdominothoracic neuroblastoma, malignant tumor of ill-defined site, neoplasm of flank, neuroblastoma, overlapping malignant neoplasm of ill-defined site , overlapping malignant neoplasm of multiple endocrine glands, etc.
The following anatomical sites found in the Table of Neoplasms apply to this code given the correct histological behavior: abdominopelvic ; back NEC ; extremity ; flank NEC ; limb ; pelvo-abdominal ; specified site NEC ; etc
Tabular List of Diseases and Injuries
The Tabular List of Diseases and Injuries is a list of ICD-10 codes, organized "head to toe" into chapters and sections with coding notes and guidance for inclusions, exclusions, descriptions and more. The following references are applicable to the code C76.8:
Inclusion TermsInclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
- Malignant neoplasm of overlapping ill-defined sites
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Abdominothoracic neuroblastoma
- Malignant tumor of ill-defined site
- Neoplasm of flank
- Overlapping malignant neoplasm of ill-defined site
- Overlapping malignant neoplasm of multiple endocrine glands
- pN1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
- pN2a category
- pN2a: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
- pN2b category
- pN2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
- pN2c category
- pN2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
- pN3: Metastasis in a lymph node, more than 6 cm in greatest dimension
- Primary malignant neoplasm of back
- Primary malignant neoplasm of flank
- Primary malignant neoplasm of trunk
- T1: Aerodigestive tract tumor < 2 cm in greatest dimension
- T1: Aerodigestive tract tumor < 2 cm in greatest dimension without extraparenchymal extension
- T2: Aerodigestive tract tumor > 2 cm but < 4 cm in greatest dimension
- T2: Aerodigestive tract tumor > 2 cm but < 4 cm in greatest dimension without extraparenchymal extension
- T2: Aerodigestive tract tumor causing bone erosion or destruction, except for the posterior antral wall, including extension into hard palate and/or middle nasal meatus
- T2: Aerodigestive tract tumor extends into nasal cavity
- T2: Aerodigestive tract tumor extends to soft tissue of oropharynx and/or nasal fossa
- T2: Aerodigestive tract tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility
- T2: Aerodigestive tract tumor extends to vocal cord with normal or impaired mobility
- T2: Aerodigestive tract tumor invades more than one subsite of hypopharynx or an adjacent site, or measures > 2 cm but < 4 cm in greatest dimension, without fixation of hemilarynx
- T2: Aerodigestive tract tumor invades mucosa of >1 adjacent subsite of supraglottis/glottis/region outside supraglottis, without fixation of larynx
- T2a: Aerodigestive tract tumor without parapharyngeal extension
- T2b: Aerodigestive tract tumor with parapharyngeal extension
- T3: Aerodigestive tract tumor > 4 cm in greatest dimension
- T3: Aerodigestive tract tumor extends to anterior orbit and/or maxillary sinus
- T3: Aerodigestive tract tumor having extraparenchymal extension without seventh nerve involvement, and/or > 4 cm but < 6 cm in greatest dimension
- T3: Aerodigestive tract tumor invades any of the following: bone of posterior wall of maxillary sinus, subcutaneous tissues, skin of cheek, floor or medial wall of orbit, infratemporal fossa, pterygoid plates, ethmoid sinuses
- T3: Aerodigestive tract tumor measures > 4 cm in greatest dimension, or with fixation of hemilarynx
- T3: Aerodigestive tumor invades bony structures and/or paranasal sinuses
- T4: Aerodigestive tract tumor invades adjacent structures
- T4: Aerodigestive tract tumor invades adjacent structures
- T4: Aerodigestive tract tumor invades orbital contents beyond the floor or medial wall including apex and/or any of the following: cribriform plate, base of skull, nasopharynx, sphenoid sinus, frontal sinus
- T4: Aerodigestive tract tumor with intracranial extension and/or involvement of cranial nerves, infratemporal fossa, hypopharynx or orbit
- T4: Aerodigestive tract tumor with intracranial extension, orbital extension including apex, involving sphenoid and/or frontal sinus and/or skin of nose
- T4: Aerodigestive tumor invades base of skull, seventh nerve, and/or exceeds 6 cm in greatest dimension
- Thoracic neuroblastoma
- Tumor of ill-defined site
Diagnostic Related Groups - MS-DRG Mapping
|MS-DRG||MS-DRG Title||MCD||Relative Weight|
|826||MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITH MCC||17||5.0368|
|827||MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITH CC||17||2.4976|
|828||MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITHOUT CC/MCC||17||1.6777|
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.
Convert C76.8 to ICD-9 Code
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C76.8 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.
Table of Neoplasms
The code C76.8 is included in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.
Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.
|»specified site NEC||C76.8||C79.89||D09.8||D36.7||D48.7||D49.89|
Information for Patients
Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for where they start. For example, lung cancer starts in the lung, and breast cancer starts in the breast. The spread of cancer from one part of the body to another is called metastasis. Symptoms and treatment depend on the cancer type and how advanced it is. Most treatment plans may include surgery, radiation and/or chemotherapy. Some may involve hormone therapy, immunotherapy or other types of biologic therapy, or stem cell transplantation.
NIH: National Cancer Institute
[Learn More in MedlinePlus]